ArticleArthritis & rheumatology (Hoboken, N.J.)2021

Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et al.

No numbers read from the abstract.

Not cited yet